Molecular mechanisms for vascular injury in the metabolic syndrome

Drugs under Experimental and Clinical Research

Volumn 31, Issue 3, 2005, Pages 123-129

  Yamagishi, Sho Ichi ^a   Nakamura, K ^a   Jinnouchi, Y ^a   Takenaka, K ^a   Imaizumi, T ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZELNIDIPINE; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LEPTIN; NIFEDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RAMIPRIL; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIUM CELL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; META ANALYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LEPTIN; METABOLIC SYNDROME X; RENIN-ANGIOTENSIN SYSTEM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21744441121     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Fernandes-Real J.M., Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endoc. Rev., 24, 278, 2003.
2. Fong T.M. Targeting metabolic syndrome. Expert. Opin. Investig. Drugs. 13, 1203, 2004.
3. Hsueh W.A., Quinones M.J. Role of endothelial dysfunction in insulin resistance. Am. J. Cardiol., 92, 10J, 2003.
4. Borst S.E. The role of TNF-alpha in insulin resistance. Endocrine, 23, 177, 2004,
5. Wisse B.E. The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol., 15, 2792, 2004.
6. Hotamisligil G.S., Murray D.L., Choy L.N., Spiegelman B.M. Tumor necrosis factor-alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA., 91, 4854, 1994.
7. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest., 95, 2409, 1995.
8. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science, 259, 87, 1993.
9. Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes, 45, 881, 1996.
10. Ross R. Atherosclerosis: An inflammatory disease. N. Eng. J. Med., 340, 115, 1999.
11. Introna M., Mantovani A. Early activation signals in endothelial cells. Arterioscler. Thromb. Vasc. Biol., 17, 423, 1997.
12. Manitovani A., Bussolino F., Dejana E. Cytokine regulation of endothelial cell function. FASEB J., 6, 2591, 1992.
13. Vanden Berghe W., Vermeulen L., De Wilde G., et al. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem. Pharmacol., 60, 1185, 2000.
14. Mackay F., Loetscher H., Stueber D., Gehr G., Lesslauer W. Tumor necrosis factor-alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type. J. Exp. Med., 177, 1277, 1992.
15. Nawroth P.P., Stern D.M. Modulation of endothelial cells hemostatic properties by tumor necrosis factor. J. Exp. Med., 163, 740, 1986.
16. Hurlimann D., Forster A., Noll G., et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation, 106, 2184, 2002
17. Kunsch C., Medford R.M. Oxidative stress as a regulator of gene expression in the vasculature. Cir. Res., 85, 753, 1999.
18. Yamagishi S., Inagaki Y., Nakamura K., et al. Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J. Mol. Cell Cardiol., 37, 497, 2004.
19. Yamagishi S., Inagaki Y., Abe R., et al. Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor-α Drugs Exp. Clin. Res., 29, 141, 2003.
20. Yamagishi S., Inagaki Y., Kikuchi S. Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exp. Clin. Res., 29, 147, 2003.
21. Yamagishi S., Takeuchi M. Nifedipine inhibits tumor necrosis factor-α-induced leukocyte adhesion to endothelial cells by suppressing vascular cell adhesion molecule-1 (VCAM-1) expression. Drugs Exp. Clin. Res., 30, 163, 2004.
22. Brown M.J., Palmer C.R., Castaigne A., et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet, 356, 366, 2000.
23. Yamagishi S., Inagaki Y., Nakamura K., Imaizumi T. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-α-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc. Pharmacol, 43, 724, 2004.
24. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature, 395, 763, 1998.
25. Nyholm B., Fisker S., Lund S., Moller N., Schmitz O. Increased circulating leptin concentrations in insulin-resistant first-degree relatives of patients with non-insulin-dependent diabetes mellitus: Relationship to body composition and insulin sensitivity but not to family history of non-insulin-dependent diabetes mellitus. Eur. J. Endocrinol., 136, 173, 1997.
26. Rudberg S., Persson B. Serum leptin levels in young females with insulin-dependent diabetes and the relationship to hyperandrogenicity and microalbuminuria. Horm. Res., 50, 297, 1998.
27. Maffei M., Halaas J., Ravussin E., et al. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med., 1, 1155, 1995.
28. Yamagishi S., Edelstein D., Du X.L., Kaneda Y., Guzman M., Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J. Biol. Chem., 276, 25096, 2001.
29. Schafer K., Halle M., Goeschen C., et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler. Thromb. Vasc. Biol., 24, 112, 2004.
30. Hasty A.H., Shimano H., Osuga J., et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J. Biol. Chem., 276, 37402, 2001.
31. Wallace A.M., McMahon A.D., Packard C.J., et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation, 104, 3052, 2001.
32. Sciacqua A., Candigliota M., Ceravolo R., et al. Weight loss in combination with physical activity improves endothelial dysfunction in human obesity. Diabetes Care, 26, 1673, 2003.
33. Khamaisi M., Wexler I.D., Skrha J., et al. Cardiovascular disease in type 2 diabetics: Epidemiology risk factors and therapeutic modalities. Isr. Med. Assoc. J., 5, 801, 2003.
34. Sowers J.R. Insulin resistance and hypertension. Am. J. Physiol. Heart. Circ. Physiol., 286, H1597, 2004.
35. Ruilope L.M., Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: A review of the clinical trial evidence. Clin. Ther., 25, 3044, 2003.
36. Silverstein R.L., Fenves A.Z., Ram C.V. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects. Postgrad. Med., 116, 31, 2004.
37. Ball S.G. Benefits of blood pressure reduction in diabetic patients. J. Hypertens., 21, S31, 2003.
38. Strazzullo P., Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr. Opin. Nephrol. Hypertens., 13, 325, 2004.
39. Benson S.C., Pershadsingh H.A., Ho C.I., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension, 43, 993, 2004.
40. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation, 109, 2054, 2004.
41. Takano H., Hasegawa H., Zou Y., Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr. Pharm. Des., 10, 2779, 2004.
42. Marx N., Duez H., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors and atherogenesis. Regulators of gene expression in vascular cells. Cir. Res., 94, 1168, 2004.
43. Zimmermann M., Unger T. Challenges in improving prognosis and therapy: The Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial programme. Expert. Opin. Pharmacother., 5, 1201, 2004.
44. Piatti P.M., Monti L.D., Galli L., et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism, 49, 748, 2000.
45. Heine R.J., Dekker J.M. Beyond postprandial hyperglycaemia: Metabolic factors associated with cardiovascular disease. Diabetologia, 45, 461, 2002,
46. Huggett R.J., Burns J., Mackintosh A.F., Mary D.A. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension, 44, 847, 2004.
47. Qiao Q., Tuomilehto J., Borch-Johnsen K. Post-challenge hyperglycemia is associated with premature death and macrovascular complications. Diabetologia, 46, M17, 2003.
48. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care, 22, 920, 1999.
49. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Lancet, 354, 617, 1999.
50. Hanefeld M., Fischer S., Julius U., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia, 39, 1577, 1996.
51. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404, 787, 2000.
52. Rosen P., Nawroth P.P., King G., et al. The role of oxidative stress in the onset and progression of diabetes and its complications: A summary of a congress series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev., 17, 189, 2001.
53. Ceriello A. Hyperglycaemia: The bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr. Metab., 12, 42, 1999.
54. Ronson R.S., Nakamura M., Vinten-Johansen J. The cardiovascular effects and implications of peroxynitrite. Cardiovasc. Res., 44, 47, 1999.
55. Creager M.A., Luscher T.F., Cosentino F., Beckman J.A. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Circulation, 108, 1527, 2003.
56. Kurowska E.M. Nitric oxide therapies in vascular diseases. Curr. Pharm. Des., 8, 155, 2002.
57. Ceriello A., Giacomello R., Stel G., et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress Diabetes, 44, 924, 1995.
58. Yamagishi S., Edelstein D., Du X.L., Brownlee M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes, 50, 1491, 2001.
59. Ceriello A., Cavarape A., Martinelli L., et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: Effects of insulin aspart. Diabet. Med., 21, 171, 2004.
60. Hanefeld M., Koehler C., Schaper F., et al. Postprandial plasma glucose is an independent risk factor for increased intima-media thickness in non-diabetic individuals. Atherosclerosis, 144, 229, 1999.
61. Bonora E., Kiechl S., Oberhollenzer F., et al. Impaired glucose tolerance, type 2 diabetes mellitus and carotid atherosclerosis: Prospective results from the Bruneck Study. Diabetologia, 43, 156, 2000.
62. Kawamori R., Yamasaki Y., Matsushima H., et al. Prevalence of carotid atherosclerosis in diabetic patients: Ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care, 15, 1290, 1992.
63. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet, 359, 2072, 2002.
64. Chiasson J.L., Josse R.G. Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA, 290, 486, 2003.
65. Hanefeld M., Chiasson J.L., Koehler C., et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke, 35, 1073, 2004.
66. Hanefeld M., Cagatay M., Petrowitsch T., et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur. Heart J., 25, 10, 2004.